INFOGRAPHIC: Jazz's road to 40% 2Q revenue rise
This article was originally published in Scrip
Executive Summary
Jazz Pharmaceuticals posted much stronger year-over-year revenue growth of 40% in the second quarter compared with 26% in the first quarter, which boosted the company's stock by 5.2% to close at $142.84 per share on 6 August.